PharmaCyte Biotech, Inc. (PMCB)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 04-30. Amounts in USD.

Revenue TTM

0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q3 '26: 0 Q4 '26: 0 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26 Q4 '26

Gross Profit TTM

-20K 0 20K 40K 60K Q1 '13: 49.7K Q2 '13: 32.6K Q3 '13: 14.5K Q4 '13: 2.5K Q1 '14: -4.1K Q2 '14: -753 Q3 '14: -753 Q4 '14: 0 Q1 '15: 0 Q2 '15: 0 Q3 '15: 0 Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q2 '13 Q1 '14 Q4 '14 Q3 '15 Q2 '16 Q1 '17 Q4 '17

Operating Income TTM

-9M -6M -3M 0 3M 6M 9M Q1 '22: -3.8M Q2 '22: -3.8M Q3 '22: -3.9M Q4 '22: -4.4M Q1 '23: -5M Q2 '23: -6.4M Q3 '23: -7.1M Q4 '23: -6.5M Q1 '24: -6.9M Q2 '24: -5.9M Q3 '24: -6.3M Q4 '24: -8.5M Q1 '25: -7.7M Q2 '25: -7.4M Q3 '25: -6.5M Q4 '25: -4.4M Q1 '26: -4M Q2 '26: -4.2M Q3 '26: -5.4M Q4 '26: -6.9M Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26 Q4 '26

Net Income TTM

-30M -15M 0 15M 30M 45M Q1 '22: -3.7M Q2 '22: -3.7M Q3 '22: -3.8M Q4 '22: -4.2M Q1 '23: -4.8M Q2 '23: -5.7M Q3 '23: -5.6M Q4 '23: -4.3M Q1 '24: -6M Q2 '24: -1.3M Q3 '24: -1.1M Q4 '24: -3.6M Q1 '25: 23.1M Q2 '25: 18.8M Q3 '25: 16.4M Q4 '25: 30.7M Q1 '26: -1.1M Q2 '26: -7.1M Q3 '26: -3.3M Q4 '26: -19.4M Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26 Q4 '26

Cost of Revenue TTM

0 15K 30K 45K Q1 '12: 40.9K Q2 '12: 44K Q3 '12: 24.3K Q4 '13: 9.6K Q1 '14: 9.6K Q2 '14: 0 Q3 '14: 0 Q4 '14: 0 Q1 '15: 0 Q2 '15: 0 Q3 '15: 0 Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q2 '12 Q1 '14 Q4 '14 Q3 '15 Q2 '16 Q1 '17 Q4 '17

Operating Cash Flow TTM

-6M -4M -2M 0 2M 4M 6M Q1 '22: -4M Q2 '22: -4.2M Q3 '22: -3.9M Q4 '22: -4.1M Q1 '23: -4M Q2 '23: -4.5M Q3 '23: -4.7M Q4 '23: -3.8M Q1 '24: -2.4M Q2 '24: -2.5M Q3 '24: -2.1M Q4 '24: -2.2M Q1 '25: -2.9M Q2 '25: -1.9M Q3 '25: -2.3M Q4 '25: -3M Q1 '26: -4.6M Q2 '26: -4.5M Q3 '26: -4.8M Q4 '26: -5.2M Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26 Q4 '26

Free Cash Flow TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 500M 1B 1.5B Q2 '20: 1.3B Q3 '20: 1.4B Q1 '21: 1.1M Q2 '21: 1.5M Q3 '21: 1.6M Q1 '22: 1.6M Q2 '22: 17.4M Q3 '22: 21.7M Q1 '23: 20.8M Q2 '23: 20.6M Q3 '23: 19M Q1 '24: 12.6M Q2 '24: 8.8M Q3 '24: 8.6M Q1 '25: 7.9M Q2 '25: 7.6M Q3 '25: 7M Q1 '26: 6.8M Q2 '26: 6.8M Q3 '26: 9.3M Q3 '20 Q3 '21 Q3 '22 Q3 '23 Q3 '24 Q3 '25 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q1 '20: 0.00 Q2 '20: 0.00 Q3 '20: 0.00 Q4 '20: -4.23 Q1 '21: -5.02 Q2 '21: -5.64 Q3 '21: -6.13 Q4 '21: -2.51 Q1 '22: -2.36 Q2 '22: -1.80 Q3 '22: -1.35 Q4 '23: -0.21 Q1 '24: -0.68 Q2 '24: -0.85 Q3 '25: 0.74 Q4 '25: 2.59 Q1 '26: -0.54 Q2 '26: -1.39 Q3 '26: -1.12 Q4 '26: -3.00 Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '24 Q1 '26 Q4 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.